<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">30000004</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK500945</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Library of Medicine (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="lactmed">Drugs and Lactation Database (LactMed)</BookTitle><PubDate><Year>2006</Year></PubDate><BeginningDate><Year>2006</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="lactmed" part="LM1351">Acalabrutinib</ArticleTitle><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>No information is available on the clinical use of acalabrutinib during breastfeeding. Because acalabrutinib is over 97% bound to plasma proteins, and the half-life of the drug and metabolite are less than 7 hours, the amount in milk is likely to be low. However, the protein binding of the active metabolite is not known and the manufacturer recommends that breastfeeding be discontinued during acalabrutinib therapy and for at least 2 weeks after the final dose.</AbstractText></Abstract><Sections><Section><SectionTitle book="lactmed" part="LM1351" sec="LM1351.drug-levels-effects">Drug Levels and Effects</SectionTitle></Section><Section><SectionTitle book="lactmed" part="LM1351" sec="LM1351.subst-id">Substance Identification</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">Acalabrutinib</Keyword><Keyword MajorTopicYN="N">Calquence</Keyword><Keyword MajorTopicYN="N">ACP-196</Keyword><Keyword MajorTopicYN="N">Acalabrutinib [INN]</Keyword><Keyword MajorTopicYN="N">UNII-I42748ELQW</Keyword><Keyword MajorTopicYN="N">1420477-60-6</Keyword><Keyword MajorTopicYN="N">Acalabrutinib [USAN:INN]</Keyword><Keyword MajorTopicYN="N">I42748ELQW</Keyword><Keyword MajorTopicYN="N">Benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-</Keyword></KeywordList><ContributionDate><Year>2018</Year><Month>12</Month><Day>3</Day></ContributionDate></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30000004</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
